Role of Allogeneic Hematopoietic Cell Transplant for Relapsed/Refractory Aggressive B-Cell Lymphomas in the CART Era

Scientists selected patients with the following characteristics: CART or allogeneic hematopoietic cell transplantation (alloHCT) performed between 2016 and 2021; ≥18 years old; aggressive B-cell lymphomas diagnosis; ≥2 lines of therapy; and either anti-CD19 CART or alloHCT as therapy at relapse.